Loading...
•
Sep 30, 2024
Mesa Labs Q2 2025 Earnings Report
Announced results for the second quarter of fiscal year 2025.
Key Takeaways
Mesa Labs reported an 8.8% increase in revenues compared to the second quarter of the previous year, driven by the acquisition of GKE. Operating income significantly increased, and the company saw sequential growth in orders. However, core organic revenues declined slightly due to shipment timing in SDC and headwinds in China.
Revenues increased by 8.8% compared to the second quarter of the previous year.
Operating income increased by 5,947% to $3,508 thousand.
Non-GAAP adjusted operating income excluding unusual items increased by 18.9%.
The acquisition of GKE contributed significantly to revenue growth, offsetting organic decline.
Mesa Labs
Mesa Labs
Mesa Labs Revenue by Segment
Revenue by Segment
Sterilization & Disinfection Control Revenue
CapyFin.comBiopharmaceutical Development Revenue
CapyFin.comCalibration Solutions Revenue
CapyFin.comClinical Genomics Revenue
CapyFin.com Forward Guidance
The company anticipates strong year-over-year growth in 3Q25 for BPD and continued sequential growth in CG, CS, and SDC, leading to strong organic revenue growth overall. They remain attuned to market shifts and continue to invest in strategic initiatives for long-term growth.
Positive Outlook
- Solid sales funnels are expected to drive strong year-over-year growth in 3Q25 for BPD.
- Continued sequential growth is expected in 3Q25 for CG, CS, and SDC.
- The company anticipates strong organic revenue growth in 3Q25.
- The company will remain highly attuned to market shifts.
- The company will continue to invest in strategic initiatives driving long term growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income